Pfizer Says Clinical Trial Shows Vaccine is Highly Effective For 6 Months
Photo by Steven Cornfield via Unsplash
An ongoing Phase 3 clinical study shows that the Pfizer vaccine is 91% effective for at least 6 months, the company announced April 1.
Vaccine experts say it is likely effective longer than that, but this data showing high protection 6 months after both shots are administered is good news.
“The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA),” Pfizer and BioNTech said in a joint statement.
The new data, from 12,000 of more than 44,000 adults in the trial, was observed from seven days through six months after receiving the second dose of the vaccine.
“The information coming from Pfizer-BioNTech is good news with evidence that those enrolled in the clinical trials last year are still protected. So we know that immunity will not be short-lived,” Dr. Peter Hotez, a vaccine expert and dean of the school of tropical medicine at Baylor College of Medicine, told CNN.
“Hopefully the protection might last years, but we won’t know until we know,” Hotez said.
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, agrees with other experts that this vaccine is highly likely to be effective longer than six months.
“They know at six months it’s clearly there. It more than likely will be even longer. Time will tell,” Fauci told CNN.
Some experts even estimate that the COVID-19 vaccine will only be necessary once in a person’s lifetime.
The Pfizer/BioNTech vaccine is 100% effective against Covid-19 in South Africa.
“The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine’s overall effectiveness,” Pfizer CEO Albert Bourla said in a statement.
Both Pfizer and Moderna will continue their clinical trials for two years, as they continue to report updated safety and efficacy data.